Sung-Jin Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sung-Jin Hong has a total of 316 co-authors. Here are the top co-authors by number of shared publications:
- Myeong-Ki Hong
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
101 shared publications - Jung-Sun Kim
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
100 shared publications - Donghoon Choi
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
98 shared publications - Young-Guk Ko
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
95 shared publications - Yangsoo Jang
Division of Cardiology, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam, Korea
94 shared publications - Byeong-Keuk Kim
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
93 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Outcomes of Second Valve Implantation as a Bail-Out Strategy for Acute Valve Migration During Transcatheter Aortic Valve Implantation: A Retrospective Multi-Center Study
Kim SO, et al. Korean Circ J. 2027 ;57:e72. https://doi.org/10.4070/kcj.2026.0218
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessOutcomes of Second Valve Implantation as a Bail-Out Strategy for Acute Valve Migration During Transcatheter Aortic Valve Implantation: A Retrospective Multi-Center Study
Kim SO, et al. Korean Circ J. 2027 ;57:e72. https://doi.org/10.4070/kcj.2026.0218
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Mid-Term Outcomes of Endovascular Aneurysm Repair With the INCRAFT Stent Graft System: Retrospective Combined Korean Multi-Center and Single-Center Registry Analysis
Jin IT, et al. Korean Circ J. 2027 ;57:e42. https://doi.org/10.4070/kcj.2026.0103
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessMid-Term Outcomes of Endovascular Aneurysm Repair With the INCRAFT Stent Graft System: Retrospective Combined Korean Multi-Center and Single-Center Registry Analysis
Jin IT, et al. Korean Circ J. 2027 ;57:e42. https://doi.org/10.4070/kcj.2026.0103
- 7 November 2026
- Published by Wolters Kluwer Health in Circulation
Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial
BACKGROUND: In a target-directed low-density lipoprotein cholesterol (LDL-C)–lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease. We compared the efficacy and safety of initial statin–ezetimibe combination therapy versus statin monotherapy within intensive or conventional LDL-C–targeting strategies. METHODS: In this prespecified second randomization of the randomized Ez-PAVE trial (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease: Randomized Comparison of LDL Cholesterol Targeting P =0.596). Patients who received statin–ezetimibe combination therapy achieved lower median LDL-C levels during follow-up than those who received statin monotherapy in both the intensive-targeting (53 mg/dL [interquartile range, 45–62 mg/dL] versus 62 mg/dL [interquartile range, 53–74 mg/dL]) and conventional-targeting (63 mg/dL [interquartile range, 55–73 mg/dL] versus 70 mg/dL [interquartile range, 62–81 mg/dL]) strategies. During follow-up, ezetimibe was added to the treatment regimen of 241 patients (34.3%) and 177 patients (24.8%) who initially received statin monotherapy in the intensive- and conventional-targeting strategies, respectively. The treatment effect of intensive-targeting versus conventional-targeting strategies was consistent regardless of therapy regimens without significant heterogeneity ( P interaction =0.583). The safety end points were similar between the groups. CONCLUSIONS: Within a target-directed LDL-C–lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin–ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04626973.
- 7 November 2026
- Published by Wolters Kluwer Health in Circulation
Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial
BACKGROUND: In a target-directed low-density lipoprotein cholesterol (LDL-C)–lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease. We compared the efficacy and safety of initial statin–ezetimibe combination therapy versus statin monotherapy within intensive or conventional LDL-C–targeting strategies. METHODS: In this prespecified second randomization of the randomized Ez-PAVE trial (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease: Randomized Comparison of LDL Cholesterol Targeting P =0.596). Patients who received statin–ezetimibe combination therapy achieved lower median LDL-C levels during follow-up than those who received statin monotherapy in both the intensive-targeting (53 mg/dL [interquartile range, 45–62 mg/dL] versus 62 mg/dL [interquartile range, 53–74 mg/dL]) and conventional-targeting (63 mg/dL [interquartile range, 55–73 mg/dL] versus 70 mg/dL [interquartile range, 62–81 mg/dL]) strategies. During follow-up, ezetimibe was added to the treatment regimen of 241 patients (34.3%) and 177 patients (24.8%) who initially received statin monotherapy in the intensive- and conventional-targeting strategies, respectively. The treatment effect of intensive-targeting versus conventional-targeting strategies was consistent regardless of therapy regimens without significant heterogeneity ( P interaction =0.583). The safety end points were similar between the groups. CONCLUSIONS: Within a target-directed LDL-C–lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin–ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04626973.
- 29 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Optimization process after angiography-guided stent implantation: pre-specified analysis of the OCCUPI randomized trial
Aims: Despite its benefits, the detailed process by which optical coherence tomography (OCT) improves stent optimization, and the role of pre-stenting OCT assessment, have not been fully investigated. We aimed (i) to assess the achievement of OCT-defined optimization criteria after angiography-guided stent implantation and (ii) to assess the role of pre-stenting OCT assessment. Methods and results: The first consecutive 200 patients in the OCT-guided arm of the OCCUPI trial were randomly assigned to the full OCT-guided or angiography-first-guided group. In the angiography-first-guided group, after achieving angiographically optimal stenting, OCT was performed to compare the achievement of OCT-defined optimization criteria between full OCT-guided percutaneous coronary intervention (PCI) and angiography-first-guided PCI. After additional procedures in the angiography-first-guided group, the stent optimization rates and 1-year clinical outcomes were compared between the full OCT-guided and angiography-first-guided groups, both of which underwent stent optimization using OCT. The optimization rate was higher in the full OCT-guided group than in the angiography-first-guided group (63.3 vs. 44.4%; P = 0.012). After optimization with OCT, the optimization rate in the angiography-first-guided group increased to 60.6% with a decrease in maximal malapposition distance and resolution of major edge dissections. Although the minimal stent area (MSA) increased after optimization with OCT in the angiography-first-guided group (MSA of OCT guidance without pre-stenting OCT), it remained smaller than that of the full OCT-guided group (MSA of OCT guidance with pre-stenting OCT). The clinical outcomes did not differ between groups. Conclusion: Angiography guidance achieved a lower optimization rate than OCT guidance. Furthermore, pre-stenting OCT may facilitate more robust stent expansion. Study registration: ClinicalTrials.gov (ID: NCT03625908).
- 29 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Optimization process after angiography-guided stent implantation: pre-specified analysis of the OCCUPI randomized trial
Aims: Despite its benefits, the detailed process by which optical coherence tomography (OCT) improves stent optimization, and the role of pre-stenting OCT assessment, have not been fully investigated. We aimed (i) to assess the achievement of OCT-defined optimization criteria after angiography-guided stent implantation and (ii) to assess the role of pre-stenting OCT assessment. Methods and results: The first consecutive 200 patients in the OCT-guided arm of the OCCUPI trial were randomly assigned to the full OCT-guided or angiography-first-guided group. In the angiography-first-guided group, after achieving angiographically optimal stenting, OCT was performed to compare the achievement of OCT-defined optimization criteria between full OCT-guided percutaneous coronary intervention (PCI) and angiography-first-guided PCI. After additional procedures in the angiography-first-guided group, the stent optimization rates and 1-year clinical outcomes were compared between the full OCT-guided and angiography-first-guided groups, both of which underwent stent optimization using OCT. The optimization rate was higher in the full OCT-guided group than in the angiography-first-guided group (63.3 vs. 44.4%; P = 0.012). After optimization with OCT, the optimization rate in the angiography-first-guided group increased to 60.6% with a decrease in maximal malapposition distance and resolution of major edge dissections. Although the minimal stent area (MSA) increased after optimization with OCT in the angiography-first-guided group (MSA of OCT guidance without pre-stenting OCT), it remained smaller than that of the full OCT-guided group (MSA of OCT guidance with pre-stenting OCT). The clinical outcomes did not differ between groups. Conclusion: Angiography guidance achieved a lower optimization rate than OCT guidance. Furthermore, pre-stenting OCT may facilitate more robust stent expansion. Study registration: ClinicalTrials.gov (ID: NCT03625908).
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (9) , e016841
Antithrombotic Therapy in Patients With Atrial Fibrillation With Prior Complex PCI: A Secondary Analysis of the Randomized ADAPT AF-DES Trial
BACKGROUND: In patients with atrial fibrillation and chronic coronary syndrome beyond 12 months after percutaneous coronary intervention (PCI), oral anticoagulant monotherapy is recommended by the guideline; however, its efficacy and safety in patients with complex PCI remain uncertain. METHODS: We conducted a post hoc analysis of the randomized ADAPT AF-DES trial (Appropriate Duration of Antiplatelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug-Eluting Stents), which compared non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy with NOAC plus clopidogrel in patients with atrial fibrillation ≥12 months after second- or third-generation drug-eluting stent implantation. Complex PCI was defined by one of the following characteristics: ≥3 stents, ≥3 lesions, bifurcation with 2 stents, total stent length ≥60 mm, left main PCI, or chronic total occlusion PCI. Net adverse clinical events, ischemic composite outcomes, and bleeding composite outcomes were evaluated according to PCI complexity. RESULTS: Among 960 patients, 247 (25.7%) underwent complex PCI and 713 (74.3%) underwent noncomplex PCI. NOAC monotherapy was associated with a lower risk of net adverse clinical events compared with combination therapy in both the complex PCI group (9.5% versus 21.5%; hazard ratio, 0.42 [95% CI, 0.21–0.83]; P =0.01) and the noncomplex PCI group (9.6% versus 15.7%; hazard ratio, 0.59 [95% CI, 0.39–0.90]; P =0.02), with no significant interaction. Ischemic outcomes were infrequent and did not differ significantly between treatment strategies regardless of PCI complexity, whereas bleeding outcomes were consistently lower with NOAC monotherapy in both complex and noncomplex PCI groups. CONCLUSIONS: In this post hoc analysis of the randomized ADAPT AF-DES trial, NOAC monotherapy beyond 12 months after PCI was associated with a substantial reduction in bleeding regardless of PCI complexity. Although limited by low absolute event rates, ischemic outcomes did not differ significantly between treatment strategies. These findings suggest that a bleeding-focused long-term antithrombotic strategy may be reasonable in patients with atrial fibrillation and chronic coronary syndrome, including those with prior complex PCI, although prospective validation remains warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04250116.
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (9) , e016841
Antithrombotic Therapy in Patients With Atrial Fibrillation With Prior Complex PCI: A Secondary Analysis of the Randomized ADAPT AF-DES Trial
BACKGROUND: In patients with atrial fibrillation and chronic coronary syndrome beyond 12 months after percutaneous coronary intervention (PCI), oral anticoagulant monotherapy is recommended by the guideline; however, its efficacy and safety in patients with complex PCI remain uncertain. METHODS: We conducted a post hoc analysis of the randomized ADAPT AF-DES trial (Appropriate Duration of Antiplatelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug-Eluting Stents), which compared non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy with NOAC plus clopidogrel in patients with atrial fibrillation ≥12 months after second- or third-generation drug-eluting stent implantation. Complex PCI was defined by one of the following characteristics: ≥3 stents, ≥3 lesions, bifurcation with 2 stents, total stent length ≥60 mm, left main PCI, or chronic total occlusion PCI. Net adverse clinical events, ischemic composite outcomes, and bleeding composite outcomes were evaluated according to PCI complexity. RESULTS: Among 960 patients, 247 (25.7%) underwent complex PCI and 713 (74.3%) underwent noncomplex PCI. NOAC monotherapy was associated with a lower risk of net adverse clinical events compared with combination therapy in both the complex PCI group (9.5% versus 21.5%; hazard ratio, 0.42 [95% CI, 0.21–0.83]; P =0.01) and the noncomplex PCI group (9.6% versus 15.7%; hazard ratio, 0.59 [95% CI, 0.39–0.90]; P =0.02), with no significant interaction. Ischemic outcomes were infrequent and did not differ significantly between treatment strategies regardless of PCI complexity, whereas bleeding outcomes were consistently lower with NOAC monotherapy in both complex and noncomplex PCI groups. CONCLUSIONS: In this post hoc analysis of the randomized ADAPT AF-DES trial, NOAC monotherapy beyond 12 months after PCI was associated with a substantial reduction in bleeding regardless of PCI complexity. Although limited by low absolute event rates, ischemic outcomes did not differ significantly between treatment strategies. These findings suggest that a bleeding-focused long-term antithrombotic strategy may be reasonable in patients with atrial fibrillation and chronic coronary syndrome, including those with prior complex PCI, although prospective validation remains warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04250116.
- Open Access
Antithrombotic Therapy in Atrial Fibrillation Patients with Prior Complex Percutaneous Coronary Intervention: A Secondary Analysis of the Randomized ADAPT AF-DES Trial
Background: In patients with atrial fibrillation (AF) and stable coronary artery disease beyond 1 year after percutaneous coronary intervention (PCI), oral anticoagulant monotherapy is guideline-recommended; however, its efficacy and safety in patients with complex PCI remain uncertain. Methods: We conducted a post-hoc analysis of the randomized ADAPT AF-DES trial comparing NOAC monotherapy versus NOAC plus clopidogrel in AF patients ≥12 months after second- or third-generation drug-eluting stent implantation. Complex PCI was defined by one of the following characteristics: ≥3 stents, ≥3 lesions, bifurcation with 2 stents, total stent length ≥60 mm, left main PCI, or chronic total occlusion PCI. Net adverse clinical events (NACE), ischemic composite outcomes, and bleeding composite outcomes were evaluated according to PCI complexity. Results: Among 960 patients, 247 (25.7%) underwent complex PCI and 713 (74.3%) underwent noncomplex PCI. NOAC monotherapy was associated with a lower risk of NACE compared with combination therapy in both the complex PCI group (9.5% vs 21.5%; hazard ratio 0.42, 95% confidence interval 0.21–0.83; P =0.01) and the noncomplex PCI group (9.6% vs 15.7%; hazard ratio 0.59, 95% confidence interval 0.39–0.90; P =0.02), with no significant interaction. Ischemic outcomes did not differ significantly between treatment strategies regardless of PCI complexity, whereas bleeding outcomes were consistently lower with NOAC monotherapy in both complex and noncomplex PCI groups. Conclusions: In this post hoc analysis of the randomized ADAPT AF-DES trial, the clinical benefits of NOAC monotherapy beyond 12 months after PCI—characterized by reduced bleeding without a significant increase in ischemic events—were consistent regardless of PCI complexity. While hypothesis-generating, these findings support a long-term antithrombotic strategy prioritizing bleeding reduction in patients with AF, irrespective of prior PCI complexity. Trial registration: URL: http://www.clinicaltrials.gov ; Unique identifier: NCT04250116 . Clinical perspective: What is new?: In a randomized population of patients with AF and prior drug-eluting stent implantation, the efficacy and safety of NOAC monotherapy versus NOAC plus clopidogrel were evaluated according to anatomic PCI complexity. Among patients with prior complex PCI, NOAC monotherapy was not associated with an increased risk of ischemic events and was associated with a substantial reduction in bleeding. What are the clinical implications?: NOAC monotherapy beyond 1 year after PCI was supported in patients with AF, including those with prior complex PCI. Long-term antithrombotic decisions may place greater emphasis on bleeding risk than PCI complexity. The optimal duration of combination antithrombotic therapy after complex PCI in patients with AF remains to be determined.
Open AccessAntithrombotic Therapy in Atrial Fibrillation Patients with Prior Complex Percutaneous Coronary Intervention: A Secondary Analysis of the Randomized ADAPT AF-DES Trial
Background: In patients with atrial fibrillation (AF) and stable coronary artery disease beyond 1 year after percutaneous coronary intervention (PCI), oral anticoagulant monotherapy is guideline-recommended; however, its efficacy and safety in patients with complex PCI remain uncertain. Methods: We conducted a post-hoc analysis of the randomized ADAPT AF-DES trial comparing NOAC monotherapy versus NOAC plus clopidogrel in AF patients ≥12 months after second- or third-generation drug-eluting stent implantation. Complex PCI was defined by one of the following characteristics: ≥3 stents, ≥3 lesions, bifurcation with 2 stents, total stent length ≥60 mm, left main PCI, or chronic total occlusion PCI. Net adverse clinical events (NACE), ischemic composite outcomes, and bleeding composite outcomes were evaluated according to PCI complexity. Results: Among 960 patients, 247 (25.7%) underwent complex PCI and 713 (74.3%) underwent noncomplex PCI. NOAC monotherapy was associated with a lower risk of NACE compared with combination therapy in both the complex PCI group (9.5% vs 21.5%; hazard ratio 0.42, 95% confidence interval 0.21–0.83; P =0.01) and the noncomplex PCI group (9.6% vs 15.7%; hazard ratio 0.59, 95% confidence interval 0.39–0.90; P =0.02), with no significant interaction. Ischemic outcomes did not differ significantly between treatment strategies regardless of PCI complexity, whereas bleeding outcomes were consistently lower with NOAC monotherapy in both complex and noncomplex PCI groups. Conclusions: In this post hoc analysis of the randomized ADAPT AF-DES trial, the clinical benefits of NOAC monotherapy beyond 12 months after PCI—characterized by reduced bleeding without a significant increase in ischemic events—were consistent regardless of PCI complexity. While hypothesis-generating, these findings support a long-term antithrombotic strategy prioritizing bleeding reduction in patients with AF, irrespective of prior PCI complexity. Trial registration: URL: http://www.clinicaltrials.gov ; Unique identifier: NCT04250116 . Clinical perspective: What is new?: In a randomized population of patients with AF and prior drug-eluting stent implantation, the efficacy and safety of NOAC monotherapy versus NOAC plus clopidogrel were evaluated according to anatomic PCI complexity. Among patients with prior complex PCI, NOAC monotherapy was not associated with an increased risk of ischemic events and was associated with a substantial reduction in bleeding. What are the clinical implications?: NOAC monotherapy beyond 1 year after PCI was supported in patients with AF, including those with prior complex PCI. Long-term antithrombotic decisions may place greater emphasis on bleeding risk than PCI complexity. The optimal duration of combination antithrombotic therapy after complex PCI in patients with AF remains to be determined.
- 1 April 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (4) , 533-542
De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome
The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive. To compare the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT from randomized clinical trials in patients with ACS. PubMed, EMBASE, Scopus, and ClinicalTrials.gov from inception to 12 December 2024. Randomized clinical trials comparing de-escalating DAPT to ticagrelor monotherapy versus ticagrelor-based standard DAPT for 12 months, specifically in patients with ACS undergoing DES implantation. The coprimary end points were an ischemic end point (composite of death, nonprocedural [spontaneous] myocardial infarction, or stroke) and a bleeding end point (Bleeding Academic Research Consortium types 3 or 5 bleeding). Individual patient data were obtained from 3 trials (TICO [Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus-Eluting Stent for Acute Coronary Syndrome], T-PASS [Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome], and ULTIMATE-DAPT [Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes]), including 9130 randomized patients with ACS; 3132 had ST-segment elevation myocardial infarction (STEMI), 3023 had non-STEMI (NSTEMI), and 2975 had unstable angina. The rate of the primary ischemic end point was not different between the ticagrelor monotherapy and standard DAPT groups (1.7% vs. 2.1%; hazard ratio [HR], 0.85 [95% CI, 0.63 to 1.16]). The rate of the primary bleeding end point was lower in the ticagrelor monotherapy group (0.8% vs. 2.5%; HR, 0.30 [CI, 0.21 to 0.45]). These findings were consistent in patients with STEMI, NSTEMI, and unstable angina. Other de-escalation strategies for modulating antiplatelet therapy were not included. In patients with ACS undergoing DES implantation, de-escalating DAPT to ticagrelor monotherapy was associated with a lower risk for major bleeding compared with standard DAPT, without an increase in ischemic events, regardless of the type of ACS. None. (PROSPERO: CRD42024565855).
- 1 April 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (4) , 533-542
De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome
The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive. To compare the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT from randomized clinical trials in patients with ACS. PubMed, EMBASE, Scopus, and ClinicalTrials.gov from inception to 12 December 2024. Randomized clinical trials comparing de-escalating DAPT to ticagrelor monotherapy versus ticagrelor-based standard DAPT for 12 months, specifically in patients with ACS undergoing DES implantation. The coprimary end points were an ischemic end point (composite of death, nonprocedural [spontaneous] myocardial infarction, or stroke) and a bleeding end point (Bleeding Academic Research Consortium types 3 or 5 bleeding). Individual patient data were obtained from 3 trials (TICO [Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus-Eluting Stent for Acute Coronary Syndrome], T-PASS [Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome], and ULTIMATE-DAPT [Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes]), including 9130 randomized patients with ACS; 3132 had ST-segment elevation myocardial infarction (STEMI), 3023 had non-STEMI (NSTEMI), and 2975 had unstable angina. The rate of the primary ischemic end point was not different between the ticagrelor monotherapy and standard DAPT groups (1.7% vs. 2.1%; hazard ratio [HR], 0.85 [95% CI, 0.63 to 1.16]). The rate of the primary bleeding end point was lower in the ticagrelor monotherapy group (0.8% vs. 2.5%; HR, 0.30 [CI, 0.21 to 0.45]). These findings were consistent in patients with STEMI, NSTEMI, and unstable angina. Other de-escalation strategies for modulating antiplatelet therapy were not included. In patients with ACS undergoing DES implantation, de-escalating DAPT to ticagrelor monotherapy was associated with a lower risk for major bleeding compared with standard DAPT, without an increase in ischemic events, regardless of the type of ACS. None. (PROSPERO: CRD42024565855).
- Open Access
- 24 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1498
Continuous Renal Replacement Therapy and Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock: Results from the Rescue Registry
Background: Cardiogenic shock (CS) frequently leads to multiorgan failure, often necessitating continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO). We evaluated the association between CRRT, ECMO, and its prognostic implication in patients with CS. Methods: A total of 1247 patients with CS were enrolled from the RESCUE (Retrospective and Prospective Observational Study to Investigate Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients with Cardiogenic Shock) registry between January 2014 and December 2018. The primary outcomes, including the 72 h and 30-day all-cause mortality rates, were analyzed in relation to the use of ECMO and CRRT among CS patients. Results: Among 751 non-ECMO patients, 90 (12%) underwent CRRT, while among 496 ECMO patients, 195 (39.3%) underwent CRRT. Overall, CRRT was associated with higher 30-day mortality. However, among ECMO patients, CRRT was linked to lower 72 h mortality (19.6% versus 12.3%; p = 0.045). Multivariate analysis showed that CRRT reduced 72 h mortality in ECMO patients (hazard ratio: 0.44; 95% confidence interval: 0.21–0.91; p = 0.027). Independent predictors for CRRT included an estimated GFR < 44 mL/min/1.73 m2, mechanical ventilation, ECMO use, IABP use, and increased lactate. Conclusions: CS patients receiving CRRT had higher 30-day mortality. Nonetheless, CRRT administration was more common in ECMO patients, potentially improving early in-hospital clinical outcomes.
- 24 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1498
Open AccessContinuous Renal Replacement Therapy and Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock: Results from the Rescue Registry
Background: Cardiogenic shock (CS) frequently leads to multiorgan failure, often necessitating continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO). We evaluated the association between CRRT, ECMO, and its prognostic implication in patients with CS. Methods: A total of 1247 patients with CS were enrolled from the RESCUE (Retrospective and Prospective Observational Study to Investigate Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients with Cardiogenic Shock) registry between January 2014 and December 2018. The primary outcomes, including the 72 h and 30-day all-cause mortality rates, were analyzed in relation to the use of ECMO and CRRT among CS patients. Results: Among 751 non-ECMO patients, 90 (12%) underwent CRRT, while among 496 ECMO patients, 195 (39.3%) underwent CRRT. Overall, CRRT was associated with higher 30-day mortality. However, among ECMO patients, CRRT was linked to lower 72 h mortality (19.6% versus 12.3%; p = 0.045). Multivariate analysis showed that CRRT reduced 72 h mortality in ECMO patients (hazard ratio: 0.44; 95% confidence interval: 0.21–0.91; p = 0.027). Independent predictors for CRRT included an estimated GFR < 44 mL/min/1.73 m2, mechanical ventilation, ECMO use, IABP use, and increased lactate. Conclusions: CS patients receiving CRRT had higher 30-day mortality. Nonetheless, CRRT administration was more common in ECMO patients, potentially improving early in-hospital clinical outcomes.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Application of Single Versus Double‐ProGlide Devices for Vascular Access Closure After Transfemoral Transcatheter Aortic Valve Implantation in Korean Patients
Background and Objectives: The double‐ProGlide technique is commonly used to achieve hemostasis in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). However, it has been associated with the rise of access‐site stenosis. Therefore, in this study, we compared the safety and effectiveness of the single‐ProGlide technique, with the option to deploy additional ProGlides if needed, to the double‐ProGlide method in patients undergoing transfemoral TAVR. Methods: In this single‐center retrospective study, we included 551 patients who underwent transfemoral TAVR from May 2016 to July 2022. Propensity score matching was performed to control for confounding factors, resulting in two matched groups of 175 patients each. Primary outcomes included the technical success of vascular closure, immediate procedural results, 30‐day clinical outcomes, and access‐related vascular complications. Results: Baseline characteristics were similar between the two groups after matching. No significant differences were observed in the immediate procedural results and 30‐day clinical outcomes in the two groups. The single‐ProGlide group showed a higher technical success rate for vascular closure (90.3% for single vs. 86.3% for double; p = 0.24) and a lower rate of any vascular complication (9.7% vs. 16.0%, p = 0.079) compared to the double‐ProGlide group, although these differences did not reach statistical significance. Female sex (odds ratio [OR] 2.87, 95% confidence interval [CI] 1.48–5.93, p = 0.003), smaller access vessel diameter (OR 0.65, 95% CI 0.50–0.82, p < 0.001), and increased number of ProGlides used (OR 4.94, 95% CI 2.46–10.6, p < 0.001) were associated with vascular closure device failure. Conclusions: The single‐ProGlide technique, with the option to use additional devices as required, appears to be a viable alternative to the double‐ProGlide technique. It demonstrated high technical success for main‐access closure and a trend toward lower vascular complication rates in transfemoral TAVR, although these differences did not reach statistical significance.
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Open AccessApplication of Single Versus Double‐ProGlide Devices for Vascular Access Closure After Transfemoral Transcatheter Aortic Valve Implantation in Korean Patients
Background and Objectives: The double‐ProGlide technique is commonly used to achieve hemostasis in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). However, it has been associated with the rise of access‐site stenosis. Therefore, in this study, we compared the safety and effectiveness of the single‐ProGlide technique, with the option to deploy additional ProGlides if needed, to the double‐ProGlide method in patients undergoing transfemoral TAVR. Methods: In this single‐center retrospective study, we included 551 patients who underwent transfemoral TAVR from May 2016 to July 2022. Propensity score matching was performed to control for confounding factors, resulting in two matched groups of 175 patients each. Primary outcomes included the technical success of vascular closure, immediate procedural results, 30‐day clinical outcomes, and access‐related vascular complications. Results: Baseline characteristics were similar between the two groups after matching. No significant differences were observed in the immediate procedural results and 30‐day clinical outcomes in the two groups. The single‐ProGlide group showed a higher technical success rate for vascular closure (90.3% for single vs. 86.3% for double; p = 0.24) and a lower rate of any vascular complication (9.7% vs. 16.0%, p = 0.079) compared to the double‐ProGlide group, although these differences did not reach statistical significance. Female sex (odds ratio [OR] 2.87, 95% confidence interval [CI] 1.48–5.93, p = 0.003), smaller access vessel diameter (OR 0.65, 95% CI 0.50–0.82, p < 0.001), and increased number of ProGlides used (OR 4.94, 95% CI 2.46–10.6, p < 0.001) were associated with vascular closure device failure. Conclusions: The single‐ProGlide technique, with the option to use additional devices as required, appears to be a viable alternative to the double‐ProGlide technique. It demonstrated high technical success for main‐access closure and a trend toward lower vascular complication rates in transfemoral TAVR, although these differences did not reach statistical significance.
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (12) , 1125-1137
Comparison of Short-term and Standard Duration Dual Antiplatelet Therapy in Elderly Patients: A Pooled Analysis of Five Korean Randomized Clinical Trials
Jin IT, et al. Korean Circ J. 2025 Jul;55:e121. https://doi.org/10.4070/kcj.2025.0093
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (12) , 1125-1137
Open AccessComparison of Short-term and Standard Duration Dual Antiplatelet Therapy in Elderly Patients: A Pooled Analysis of Five Korean Randomized Clinical Trials
Jin IT, et al. Korean Circ J. 2025 Jul;55:e121. https://doi.org/10.4070/kcj.2025.0093